Back to Journals » Clinical Ophthalmology » Volume 5

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Authors Kenji Inoue, Mieko Masumoto, Masato Wakakura, et al

Published 22 March 2011 Volume 2011:5 Pages 393—396

DOI https://doi.org/10.2147/OPTH.S17527

Review by Single-blind

Peer reviewer comments 4

Kenji Inoue1,3, Mieko Masumoto1,3, Masato Wakakura1, Goji Tomita2, On behalf of the Ochanomizu Ophthalmology Study Group3
1
Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan; 3Ochanomizu Ophthalmology, Tokyo, Japan

Purpose: To prospectively evaluate the safety, hypotensive effect, and preservation of visual fields of dorzolamide when added to latanoprost.
Subjects and methods: This study included 46 patients (46 eyes) with primary open-angle glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The mean deviation shown by Humphrey perimetry was compared before and after twelve months of treatment. Adverse reactions were monitored over the 12-month study period.
Results: The mean baseline IOP was 17.2 ± 3.0 mmHg while those after 3, 6 and 12 months of treatment were 14.9 ± 3.0 mmHg, 14.5 ± 3.2 mmHg, and 14.6 ± 2.6 mmHg respectively (P < 0.0001, 1-ß(power) = 0.9999571). The absolute reduction of IOP and the percent reduction were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry was similar before and after twelve months of treatment. Three patients discontinued dorzolamide therapy due to elevation of IOP and one patient discontinued it because of adverse reactions.
Conclusion: Dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angle glaucoma.

Keywords: dorzolamide, primary open-angle glaucoma, latanoprost
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma

Inoue K, Shiokawa M, Fujimoto T, Tomita G

Clinical Ophthalmology 2014, 8:1179-1183

Published Date: 19 June 2014

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma

Inoue K, Tanaka A, Tomita G

Clinical Ophthalmology 2013, 7:1411-1416

Published Date: 9 July 2013

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Inoue K, Iwasa M, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:1315-1319

Published Date: 15 August 2012

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

Inoue K, Fujimoto T, Higa R, Moriyama R, Kohmoto H, Nagumo H, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:771-775

Published Date: 21 May 2012

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension

Inoue K, Shiokawa M, Sugahara M, Higa R, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:111-116

Published Date: 12 January 2012

Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma

Inoue K, Noguchi K, Wakakura M, Tomita G

Clinical Ophthalmology 2011, 5:1211-1216

Published Date: 26 August 2011

Effects of unoprostone on diurnal variation of intraocular pressure in healthy volunteers

Inoue K, Noguchi K, Wakakura M, Tomita G

Clinical Ophthalmology 2011, 5:1003-1005

Published Date: 15 July 2011

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010